免疫组织化学检测在NSCLC鉴别诊断中的应用

Application of Immunohistochemistry in Differential Diagnosis of NSCLC

目的探讨免疫组织化学检测在非小细胞肺癌(nonsmallcelllungcancer,NSCLC)临床鉴别诊断中的应用价值。方法以我院2018年1月—2019年8月期间经病理检查确诊为非小细胞肺癌的120例患者为研究对象,其中鳞癌组59例,腺癌组61例,通过免疫组化Envi-sion二步法检测活检标本,分析腺癌、鳞癌患者的蛋白表达情况。结果腺癌组患者在TTF-1、NapsinA方面的阳性表达率更高,而鳞癌组患者在P63、CK5/6方面的阳性表达率更高,二者对比,组间差异存在明显的统计学意义(P<0.05)。结论以免疫组织化学检测方法检测肺癌活检标本,观察非小细胞肺癌中蛋白的具体表达,可以有效鉴别鳞癌、腺癌,提供确诊率,有利于患者的后期治疗。

Objective To explore the value of immunohistochemistry in the differential diagnosis of non-small cell lung cancer(NSCLC).Methods A total of 120 patients with non-small cell lung cancer diagnosed by pathology from January 2018 to August 2019 were enrolled in the study,including 59 patients with squamous cell carcinoma and 61 patients with adenocarcinoma.The Envi-sion two-step method was used to detect biopsy specimens and analyze the protein expression of patients with adenocarcinoma and squamous cell carcinoma.Results The positive expression rate of TTF-1 and NapsinA was higher in the adenocarcinoma group,while the positive expression rate in P63 and CK5/6 was higher in the squamous cell carcinoma group.There was significant statistical difference between the two groups(P<0.05).Conclusion Immunohistochemical detection of lung cancer biopsy specimens to observe the specific expression of protein in non-small cell lung cancer can effectively identify squamous cell carcinoma and adenocarcinoma,and provide a diagnosis rate,which is conducive to the patient’s later treatment.